文献速递心律失常心力衰竭与心肌病血脂与心血管预防

伊布替尼相关心血管毒性:药物警戒数据库的不比例性分析

Cardiovascular Toxicities Associated With Ibrutinib.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

该研究利用VigiBase药物警戒数据库,采用报告比值比(ROR)和信息成分(IC)进行不比例性分析,评估伊布替尼与心血管不良药物反应(CV-ADR)的关联。共识别303例伊布替尼相关心血管死亡,伊布替尼与室上性心律失常、中枢神经系统出血事件、心力衰竭、室性心律失常、传导障碍、中枢神经系统缺血事件及高血压的报告显著增加相关,且CV-ADR常发生于用药早期,部分可致命。

要点

  • 伊布替尼与室上性心律失常报告关联最强(ROR 23.1),其次为室性心律失常、中枢神经系统出血、心衰等。
  • CV-ADR多发生于伊布替尼给药后早期,相关死亡比例约10%(室上性/室性心律失常)至约20%(中枢事件、心衰、传导障碍)。
  • 伊布替尼相关室上性心律失常合并中枢事件时预后差,52例中15例死亡(28.8%)。

核心结论

  • 暴露于伊布替尼的患者可发生严重且偶发致命的心脏事件,应在患者管理和临床试验设计中予以考虑。

研究设计与样本

  • 本研究利用VigiBase国际药物警戒数据库,采用报告比值比(ROR)和信息成分(IC)进行不比例性分析,评估伊布替尼与CV-ADR及CV-ADR死亡的关联。

主要发现

  • 共识别303例伊布替尼相关心血管死亡。
  • 伊布替尼与室上性心律失常报告增加相关(ROR: 23.1; 95%CI: 21.6-24.7; p<0.0001; IC025: 3.97)。
  • 伊布替尼与中枢神经系统出血事件报告增加相关(ROR: 3.7; 95%CI: 3.4-4.1; p<0.0001; IC025: 1.63)。
  • 伊布替尼与心力衰竭报告增加相关(ROR: 3.5; 95%CI: 3.1-3.8; p<0.0001; IC025: 1.46)。
  • 伊布替尼与室性心律失常报告增加相关(ROR: 4.7; 95%CI: 3.7-5.9; p<0.0001; IC025: 0.96)。

临床怎么用

  • 使用伊布替尼的患者应警惕严重心血管不良事件,尤其在用药早期。
  • 伊布替尼治疗期间出现室上性心律失常需关注是否合并中枢神经系统事件,因其提示预后不良。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ibrutinib has revolutionized treatment for several B-cell malignancies. However, a recent clinical trial where ibrutinib was used in a front-line setting showed increased mortality during treatment compared with conventional chemotherapy. Cardiovascular toxicities were suspected as the culprit but not directly assessed in the study. OBJECTIVES: The purpose of this study was to identify and characterize cardiovascular adverse drug reactions (CV-ADR) associated with ibrutinib. METHODS: This study utilized VigiBase (International pharmacovigilance database) and performed a disproportionality analysis using reporting odds ratios (ROR) and information component (IC) to determine whether CV-ADR and CV-ADR deaths were associated with ibrutinib. IC compares observed and expected values to find associations between drugs and adverse drug reactions using disproportionate Bayesian-reporting; IC025 (lower end of the IC 95% credibility interval) >0 is significant. RESULTS: This study identified 303 ibrutinib-associated cardiovascular deaths. Ibrutinib was associated with higher reporting of supraventricular arrhythmias (SVAs) (ROR: 23.1; 95% confidence interval: 21.6 to 24.7; p < 0.0001; IC025: 3.97), central nervous system (CNS) hemorrhagic events (ROR: 3.7; 95% confidence interval: 3.4 to 4.1; p < 0.0001; IC025: 1.63), heart failure (ROR: 3.5; 95% confidence interval: 3.1 to 3.8; p < 0.0001; IC025: 1.46), ventricular arrhythmias (ROR: 4.7; 95% confidence interval: 3.7 to 5.9; p < 0.0001; IC025: 0.96), conduction disorders (ROR: 3.5; 95% confidence interval: 2.7 to 4.6; p < 0.0001; IC025: 0.76), CNS ischemic events (ROR: 2.2; 95% confidence interval: 2.0 to 2.5; p < 0.0001; IC025: 0.73), and hypertension (ROR: 1.7; 95% confidence interval: 1.5 to 1.9; p < 0.0001; IC025: 0.4). CV-ADR often occurred early after ibrutinib administration. Importantly, CV-ADR were associated with fatalities that ranged from ∼10% (SVAs and ventricular arrhythmias) to ∼20% (CNS events, heart failure, and conduction disorders). Ibrutinib-associated SVA portends poor prognosis when CNS events occur concomitantly, with 28.8% deaths (15 of 52 cases). CONCLUSIONS: Severe and occasionally fatal cardiac events occur in patients exposed to ibrutinib. These events should be considered in patient care and in clinical trial designs. (Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents [EROCA]; NCT03530215).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol. 2019. PMID: 31558250. doi:10.1016/j.jacc.2019.07.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。